ProPhase Labs (NASDAQ:PRPH - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.21, Zacks reports. The business had revenue of $3.63 million during the quarter, compared to the consensus estimate of $9.86 million. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%. During the same quarter last year, the firm posted $0.03 EPS.
ProPhase Labs Price Performance
Shares of PRPH traded up $0.13 during midday trading on Friday, hitting $5.05. 32,777 shares of the company traded hands, compared to its average volume of 107,588. The stock has a 50-day moving average of $5.57 and a 200-day moving average of $5.05. ProPhase Labs has a one year low of $4.05 and a one year high of $9.94. The firm has a market cap of $91.15 million, a P/E ratio of -5.15 and a beta of -0.17. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.28 and a quick ratio of 2.10.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "buy" rating and set a $11.00 price objective on shares of ProPhase Labs in a report on Wednesday, February 21st.
View Our Latest Research Report on PRPH
About ProPhase Labs
(
Get Free Report)
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ProPhase Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProPhase Labs wasn't on the list.
While ProPhase Labs currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
